Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
溶血磷脂酸对卵巢癌脂肪生成的调节
基本信息
- 批准号:8177055
- 负责人:
- 金额:$ 16.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-16 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseAblationAcetyl Coenzyme AAcetyl-CoA CarboxylaseAdvanced Malignant NeoplasmAnabolismAnorexiaApoptosisAscitesAttenuatedBinding ProteinsBiologicalBiological ProcessBlood CirculationBody Weight decreasedCancer PatientCancer cell lineCancerousCatabolismCell Cycle ArrestCommitEnergy MetabolismEnzymesEpithelial CellsEpitheliumExhibitsFatigueFatty AcidsFatty-acid synthaseGrowthGrowth FactorHumanHyperactive behaviorInflammatoryLinkLipidsLysophosphatidic Acid ReceptorsLysophospholipidsMaintenanceMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMalonyl Coenzyme AMediatingMediator of activation proteinMetabolismMolecularMusNormal tissue morphologyNutritionalOvarianPalmitatesPathway interactionsPatient CarePatientsPeritoneal FluidPlayProtein DephosphorylationProteinsRegulationRegulatory ElementRoleSignal TransductionStagingSterolsTissuesTranslatingTumor TissueTumorigenicityUp-RegulationXenograft Modelcancer cellchemotherapeutic agentcytotoxicdimerin vivoinhibitor/antagonistinnovationkillingslipid biosynthesislysophosphatidic acidmalignant phenotypemeetingsneoplastic cellnoveloutcome forecastovarian neoplasmreceptor expressiontumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): One of the most common molecular changes in tumor cells is the heightened rate of endogenous lipid synthesis mediated by increased expression and activity of key lipogenic enzymes, primarily fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). The lipogenic aberration occurs at early stages of tumorigenesis, becomes more pronounced in advanced cancer, and correlates with poor prognosis of patients. Furthermore, tumor cells depend heavily on or are "addicted" to de novo lipid synthesis, irrespective of the nutritional supplies. Inhibitors of FAS and ACC exhibit anti-tumor effects in culture and in mouse xenograft models. However, one barrier to applying these inhibitors to cancer patient care is their non-selective suppression of lipid synthesis in both normal and cancerous tissues, which could deteriorate weight loss, anorexia, fatigue and other cancer-associated complications.
In our preliminary studies, lysophosphatidic acid (LPA), a growth factor-like mediator present in ascites of ovarian cancer patients, stimulated de novo lipid synthesis in ovarian cancer cells through regulation of the sterol regulatory element binding protein (SREBP)-FAS and the AMP-activated kinase (AMPK)-ACC pathways. These effects of LPA on SREBP-FAS and AMPK-ACC were absent from normal or immortalized ovarian epithelial cells. Several LPA receptors are abnormally expressed in ovarian cancer compared to the normal ovarian epithelium. We therefore hypothesize that aberrant LPA signaling activates lipogenic pathways to contribute to the malignant phenotype of ovarian cancer cells. Manipulation of LPA signaling could offer an opportunity to attenuate lipid synthesis in a cancer cell-specific manner. The hypothesis will be examined through completion of the following two specific aims: 1) To elucidate the signal transduction mechanism underlying LPA-driven lipogenesis in ovarian cancer cells; and 2) To determine the biological relevance of LPA-mediated lipogenesis to ovarian cancer.
We will first identify the LPA receptor(s) and the intracellular intermediates responsible for LPA activation of the SREBP-FAS and AMPK-ACC cascades. Both molecular and pharmacological approaches will be employed to assess the effects of manipulating LPA receptor expression, sterol availability, and energy metabolism. In Aim 2, we will target the involved LPA receptor(s), LPA catabolism and other signaling players identified in Aim 1 to determine the functional impacts of interference with LPA-induced lipogenesis.
The mechanism for the upregulation of lipid synthesis in cancer is poorly defined. This study will answer whether LPA is a pathophysiological determinant of the hyperactive lipogenesis in ovarian cancer. The results could be translated into a novel and innovative approach to targeting tumor-specific lipogenesis.
PUBLIC HEALTH RELEVANCE: We recently found that lysophosphatidic acid (LPA), a growth factor-like mediator present at high levels in ascitic fluids of ovarian cancer patients, stimulates de novo lipid synthesis in ovarian cancer cells via activation of prominent lipogenic pathways. The current application will determine the mechanism for LPA-mediated lipogenesis and explore its relevance to ovarian tumorigenesis. The completion of the proposed studies will likely identify a novel biological function of LPA and offers a tempting approach to subvert the aberrant lipogenesis in a cancer cell-specific manner. )
描述(由申请人提供):肿瘤细胞中最常见的分子变化之一是内源性脂质合成速率升高,其由关键脂肪生成酶(主要是脂肪酸合酶(FAS)和乙酰辅酶A羧化酶(ACC))的表达和活性增加介导。脂肪生成异常发生在肿瘤发生的早期阶段,在晚期癌症中变得更加明显,并且与患者的不良预后相关。此外,肿瘤细胞严重依赖于或“沉迷于”从头脂质合成,而不管营养供应如何。FAS和ACC的抑制剂在培养物和小鼠异种移植模型中表现出抗肿瘤作用。然而,将这些抑制剂应用于癌症患者护理的一个障碍是它们对正常和癌组织中的脂质合成的非选择性抑制,这可能使体重减轻、厌食、疲劳和其他癌症相关并发症恶化。
在我们的初步研究中,溶血磷脂酸(LPA),生长因子样介质存在于卵巢癌患者的腹水中,刺激从头脂质合成在卵巢癌细胞通过调节固醇调节元件结合蛋白(SREBP)-FAS和AMP激活激酶(AMPK)-ACC途径。LPA对SREBP-FAS和AMPK-ACC的这些作用在正常或永生化卵巢上皮细胞中不存在。与正常卵巢上皮相比,几种LPA受体在卵巢癌中异常表达。因此,我们假设异常LPA信号激活脂肪生成途径,有助于卵巢癌细胞的恶性表型。LPA信号的操纵可以提供以癌细胞特异性方式减弱脂质合成的机会。该假设将通过完成以下两个具体目标来检验:1)阐明卵巢癌细胞中LPA驱动的脂肪生成的信号转导机制;和2)确定LPA介导的脂肪生成与卵巢癌的生物学相关性。
我们将首先鉴定LPA受体和负责LPA激活SREBP-FAS和AMPK-ACC级联的细胞内中间体。将采用分子和药理学方法来评估操纵LPA受体表达、固醇利用率和能量代谢的影响。在目标2中,我们将靶向目标1中鉴定的相关LPA受体、LPA催化剂和其他信号传导参与者,以确定干扰LPA诱导的脂肪生成的功能影响。
癌症中脂质合成上调的机制尚不清楚。本研究将回答LPA是否是卵巢癌过度脂肪生成的病理生理决定因素。这些结果可以转化为一种新的和创新的方法来靶向肿瘤特异性脂肪生成。
公共卫生相关性:我们最近发现,溶血磷脂酸(LPA),生长因子样介质目前在卵巢癌患者的腹水中的高水平,刺激卵巢癌细胞的从头脂质合成通过激活突出的脂肪生成途径。本申请将确定LPA介导的脂肪生成的机制,并探索其与卵巢肿瘤发生的相关性。这些研究的完成可能会发现LPA的一种新的生物学功能,并提供一种诱人的方法来以癌细胞特异性的方式颠覆异常的脂肪生成。)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIANJUN FANG其他文献
XIANJUN FANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIANJUN FANG', 18)}}的其他基金
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
脂肪酸β-氧化代谢重编程以改善癌症免疫治疗
- 批准号:
10599149 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
脂肪酸β-氧化代谢重编程以改善癌症免疫治疗
- 批准号:
10361537 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
溶血磷脂酸对卵巢癌脂肪生成的调节
- 批准号:
8333999 - 财政年份:2011
- 资助金额:
$ 16.26万 - 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
- 批准号:
7241458 - 财政年份:2004
- 资助金额:
$ 16.26万 - 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
- 批准号:
6774357 - 财政年份:2004
- 资助金额:
$ 16.26万 - 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
- 批准号:
7104837 - 财政年份:2004
- 资助金额:
$ 16.26万 - 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
- 批准号:
6919241 - 财政年份:2004
- 资助金额:
$ 16.26万 - 项目类别:
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 16.26万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 16.26万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 16.26万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 16.26万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 16.26万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 16.26万 - 项目类别:
Studentship Programs